Month: July 2026

Albus Health’s CEO, Mikesh Udani, explains to Diana Andrade of Clinical Trial Vanguard, how the company’s passive, contactless bedside device is reshaping what clinical trials can measure at home by prioritizing privacy from the outset. The system captures sleep, respiratory metrics, cough and other symptoms without wearables or patient effort, enabling long‑term, clinically accurate monitoring that was previously only possible in sleep labs—crucial for paediatrics, rare diseases, oncology and chronic conditions where nighttime symptoms signal deterioration or treatment response.

Udani emphasises that privacy‑by‑design is both an ethical foundation and a commercial differentiator: Albus collects only anonymised symptom data, meets stringent global regulatory standards, and consistently earns high patient trust. This combination of passive monitoring, rigorous data protection and patient‑centred design is allowing pharma sponsors to run more inclusive, lower‑burden, higher‑quality trials across more than 40 countries.

Read the full article here. 

CuraCell's head of clinical operations, Torbjörn Ström, spoke with Clinical Leader Executive Editor Abby Proch about the company’s efforts to reshape the future of T‑cell therapy for cold solid tumors. The interview explores how CuraCell’s CytoPLY platform rejuvenates a patient’s own tumor‑infiltrating lymphocytes (TILs), improving their expansion, potency, and cytokine production without genetic modification — a strategy designed to overcome the limitations of conventional cell therapies.

Ström highlights encouraging early activity across prostate cancer, glioblastoma, pancreatic cancer, and renal cell carcinoma, supporting CuraCell’s belief that a “polyclonal, unselected TIL approach may have broader applicability than many targeted therapies.” These insights have shaped CC‑38, the company’s first clinical candidate now in Phase I/IIa trials, which uses gentler preconditioning, multi‑dose administration, and a streamlined manufacturing process to reduce treatment burden and expand access for patients with cold solid tumors.

Read the full conversation here.

In pharmaphorum, reporter Nicole Raleigh spotlights Gothenburg’s rise as one of Europe’s most dynamic life sciences hubs, describing how the region now accounts for more than a third of Sweden’s total business R&D expenditure. Her piece highlights the country’s broader momentum — from major acquisitions and government sustainability investments to cutting‑edge academic research and biotech breakthroughs — illustrating how Sweden’s collaborative model between industry, academia and the public sector continues to fuel innovation.

Raleigh’s visit to GoCo Health Innovation City showcases this ecosystem in action, including Thermo Fisher Scientific’s newly opened bioanalytical laboratory and its partnership with AstraZeneca’s BioVentureHub. Leaders from both organisations outline how co‑location, shared capabilities and Sweden’s deep talent pool create ideal conditions for next‑generation drug development, digital health integration and cross‑sector innovation. The article frames Gothenburg as a uniquely fertile environment where global companies, start‑ups and researchers converge — and where Sweden’s culture of openness and resource‑sharing is driving life sciences growth well beyond its size.

Read the full article here.

In ONdrugDelivery, Nanexa’s Anders Johansson, Polla Rouf and Oliver Hedge outline how the company’s PharmaShell ALD nanocoating technology is enabling once‑monthly — and potentially once‑quarterly — injectable therapies. The authors explain how ultra‑thin, inorganic ALD coatings applied to drug microparticles create highly controlled depot formulations that dissolve at a tuned rate, delivering steady drug release over weeks to months. By avoiding polymer‑based systems and their unpredictable burst‑and‑tail behaviour, PharmaShell achieves flatter pharmacokinetic profiles, reduced peak‑related side effects and significantly lower dosing frequency.

The article highlights Nanexa’s progress with long‑acting GLP‑1 therapies, including a once‑monthly semaglutide depot supported by preclinical data and earlier clinical proof‑of‑concept from a PharmaShell‑coated liraglutide study. Recent formulation advances have produced near‑linear 30‑day release, improved tolerability and a ready‑to‑use suspension compatible with fine‑gauge needles and autoinjectors. With scale‑up plans underway and device integration progressing, the authors position PharmaShell as a next‑generation delivery platform capable of transforming chronic disease management through smarter, ultra‑long‑acting injectables.

Read the full article here.